<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170064</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-202</org_study_id>
    <nct_id>NCT02170064</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Efficacy and Tolerability of BIA 2-093</brief_title>
  <official_title>Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate
      in children and adolescents with epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study was planned to be performed as an open-label, single-centre,
      multiple-dose study, in 30 paediatric epileptic patients distributed by 3 age groups of 10
      patients each: 2-6 years [Group 1], 7-11 years [Group 2], and 12-17 years [Group 3].

      The study was constituted by a 4-week baseline phase, followed by 3 consecutive 4-week
      treatment periods with Eslicarbazepine acetate in which patients received Eslicarbazepine
      acetate once-daily at the following dosage regimens: 5 mg/kg/day (weeks 1-4), 15 mg/kg/day
      (weeks 5-8) and 30 mg/kg/day or 1800 mg/day, whichever less (weeks 9-12). At the end of each
      4-week treatment period, patients were hospitalised and serial blood samples for drug assays
      were obtained over a dosing interval.

      After the last treatment period or in the event of premature discontinuation, the dose had to
      be down-titrated during a 2-week period. After the last treatment period patient could
      continue receiving Eslicarbazepine acetate (&quot;compassionate use&quot;) if both
      parent(s)/guardian(s) /patient and his/her physician agreed this was in the best patient's
      interest. A follow-up visit occurred approximately 4 weeks after the last hospitalisation or
      early discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Drug Concentration (Cmax) Post-dose</measure>
    <time_frame>pre-dose, and ½, 1½, 3, 4½, 6 and 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax).</measure>
    <time_frame>pre-dose, and ½, 1½, 3, 4½, 6 and 12 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Seizure Frequency During Each 4-week Treatment Period Compared to the Baseline Phase</measure>
    <time_frame>Baseline, end of 5 mg/kg/day treatment period (4 weeks), 15 mg/kg/day treatment period (4 weeks) and 30 mg/kg/day treatment period (4 weeks).</time_frame>
    <description>The efficacy variables were the percentage change in seizure frequency during each 4-week treatment period compared to the baseline phase.
Seizures were recorded in the patient's diary during the baseline phase and during the following 4-week treatment periods.
Seizure frequency for each patient was standardised to a frequency per 28 days period (i.e., mean daily frequency multiplied by 28). Changes in seizure frequency were analysed for each age group separately.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1 (2-6 yrs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (&quot;compassionate use&quot;) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (7-11 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (&quot;compassionate use&quot;) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (12-17 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (&quot;compassionate use&quot;) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093 (Eslicarbazepine acetate)</intervention_name>
    <description>Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route</description>
    <arm_group_label>Group 1 (2-6 yrs)</arm_group_label>
    <arm_group_label>Group 2 (7-11 years)</arm_group_label>
    <arm_group_label>Group 3 (12-17 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The following inclusion criteria were applied in selecting patients for participation in
        the trial.

        Patient was eligible for entry into the baseline phase if he/she fulfilled the following
        criteria at Visit 1:

          -  Written informed consent given by the parent(s)/guardian(s), and by the patient when
             appropriate.

          -  Male or female patient aged between 2 and 17 years.

          -  Body weight within the 10th and 90th percentiles, by age and sex.

          -  A documented diagnosis of partial-onset seizures (simple or complex seizures with or
             without secondary generalisation), classified according to the International
             Classification of Epileptic Seizures.

          -  Currently treated with 1 to 3 AEDs (any except OXC or CBZ), in a stable dosage regimen
             during at least 1 month prior to screening.

          -  Good general health (apart from epilepsy) based on medical history and physical
             examination.

          -  In case of a female patient, she was premenarchal, surgically sterile or presented a
             urine pregnancy test consistent with a non-gravid state and practiced an effective
             non-hormonal contraception method.

        At Visit 2, patient was eligible for entry into the Eslicarbazepine acetate treatment phase
        if he/she fulfilled the following criteria:

          -  At least 4 partial-onset seizures during the last 4 weeks of the baseline phase.

          -  Brain CT scan or MRI that excluded rapidly progressive neurological diseases.

          -  ECG without clinically significant abnormalities.

          -  Good general health (apart from epilepsy) based on medical history, physical
             examination and laboratory tests at screening.

          -  Diaries satisfactorily completed by the patient or his/her caregiver during the
             baseline phase.

          -  Satisfactory compliance with the study requirements during the baseline phase.

          -  In case of a female patient of childbearing potential, she presented a urine pregnancy
             test consistent with a non-gravid state and practiced an effective non-hormonal
             contraception method.

        Exclusion Criteria:

        Patient was not allowed for entry into the screening phase if he/she fulfilled the
        following criteria at Visit 1:

          -  Primarily generalised epilepsy.

          -  Clinically relevant medical condition, other than epilepsy.

          -  History of status epilepticus in the last 3 months.

          -  History of suicide attempt.

          -  History of alcohol or drug abuse.

          -  History of hypersensitivity or intolerance to OXC or CBZ.

          -  Use of any investigational drug or participated in any clinical trial within the
             previous 2 months.

          -  Patient and/or his/her caregiver(s) unlikely to co-operate with the requirements of
             the study.

          -  If female, she was sexually active and of child-bearing potential and she did not use
             reliable contraception.

          -  Patients with non-epileptic attacks (syncopes, pseudoseizures).

          -  Previous poor compliance with anti-epileptic therapy.

          -  Need for rescue benzodiazepines more frequently than twice per week on average.

          -  Previous use of Eslicarbazepine acetate or participation in a clinical study with
             Eslicarbazepine acetate.

          -  Any other condition or circumstance that, in the opinion of the investigator, might
             compromise the patient's ability to comply with the clinical trial protocol (CTP).

        At Visit 2, patient was not eligible for entry into the Eslicarbazepine acetate treatment
        phase if he/she fulfilled the following criteria:

          -  Inadequate compliance to concomitant AEDs during the baseline phase.

          -  Clinically relevant clinical laboratory test abnormalities at screening.

          -  Occurrence of any other condition or circumstance that, in the opinion of the
             investigator, might compromise the patient's ability to comply with the CTP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinica de Neurologie Pediatrica, Spitalul &quot;Alexandru Obregia&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <results_first_submitted>July 18, 2014</results_first_submitted>
  <results_first_submitted_qc>August 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>BIA 2-093</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (2-6 Yrs)</title>
          <description>At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5–8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9–12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (“compassionate use”) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient’s interest.
For Group 1 (2–6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (7-11 Years)</title>
          <description>At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5–8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9–12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (“compassionate use”) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient’s interest.
For Group 2 (7–11 years) and Group 3 (12–17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (12-17 Years)</title>
          <description>At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5–8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9–12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (“compassionate use”) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient’s interest.
For Group 2 (7–11 years) and Group 3 (12–17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population (SP)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Population (PKP)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Efficacy Population (EP)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (2-6 Yrs)</title>
          <description>Efficacy population (EP)</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (7-11 Yrs)</title>
          <description>Efficacy population (EP)</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (12-17 Yrs)</title>
          <description>Efficacy population (EP)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.38"/>
                    <measurement group_id="B2" value="9.1" spread="1.55"/>
                    <measurement group_id="B3" value="14.5" spread="1.58"/>
                    <measurement group_id="B4" value="9.1" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Drug Concentration (Cmax) Post-dose</title>
        <time_frame>pre-dose, and ½, 1½, 3, 4½, 6 and 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (2-6 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (7-11 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (12-17 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Drug Concentration (Cmax) Post-dose</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dosage regimen 5 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6921" spread="1794"/>
                    <measurement group_id="O2" value="4820" spread="1693"/>
                    <measurement group_id="O3" value="6382" spread="1854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage regimen 15 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16183" spread="2609"/>
                    <measurement group_id="O2" value="16395" spread="3680"/>
                    <measurement group_id="O3" value="17194" spread="3410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage regimen 30 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29935" spread="4627"/>
                    <measurement group_id="O2" value="26890" spread="6944"/>
                    <measurement group_id="O3" value="32400" spread="6005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Occurrence of Cmax (Tmax).</title>
        <time_frame>pre-dose, and ½, 1½, 3, 4½, 6 and 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (2-6 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (7-11 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (12-17 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax).</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dosage regimen 5 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1"/>
                    <measurement group_id="O2" value="2" spread="1"/>
                    <measurement group_id="O3" value="2" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage regimen 15 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1"/>
                    <measurement group_id="O2" value="3" spread="1"/>
                    <measurement group_id="O3" value="2" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage regimen 30 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="3" spread="1"/>
                    <measurement group_id="O3" value="3" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Seizure Frequency During Each 4-week Treatment Period Compared to the Baseline Phase</title>
        <description>The efficacy variables were the percentage change in seizure frequency during each 4-week treatment period compared to the baseline phase.
Seizures were recorded in the patient’s diary during the baseline phase and during the following 4-week treatment periods.
Seizure frequency for each patient was standardised to a frequency per 28 days period (i.e., mean daily frequency multiplied by 28). Changes in seizure frequency were analysed for each age group separately.</description>
        <time_frame>Baseline, end of 5 mg/kg/day treatment period (4 weeks), 15 mg/kg/day treatment period (4 weeks) and 30 mg/kg/day treatment period (4 weeks).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (2-6 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (7-11 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (12-17 Yrs)</title>
            <description>Efficacy population (EP)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Seizure Frequency During Each 4-week Treatment Period Compared to the Baseline Phase</title>
          <description>The efficacy variables were the percentage change in seizure frequency during each 4-week treatment period compared to the baseline phase.
Seizures were recorded in the patient’s diary during the baseline phase and during the following 4-week treatment periods.
Seizure frequency for each patient was standardised to a frequency per 28 days period (i.e., mean daily frequency multiplied by 28). Changes in seizure frequency were analysed for each age group separately.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5Dosage regimen 5 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.2" lower_limit="-60" upper_limit="13"/>
                    <measurement group_id="O2" value="-11.7" lower_limit="-20.0" upper_limit="278.2"/>
                    <measurement group_id="O3" value="-17.1" lower_limit="-56" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage regimen 15 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" lower_limit="-93" upper_limit="-6"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-55.6" upper_limit="344.6"/>
                    <measurement group_id="O3" value="-31.7" lower_limit="-71" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage regimen 30 mg/kg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.6" lower_limit="-86" upper_limit="-4"/>
                    <measurement group_id="O2" value="12.2" lower_limit="-100.0" upper_limit="166.7"/>
                    <measurement group_id="O3" value="-43.1" lower_limit="-77" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (2-6 Yrs)</title>
          <description>Safety population (SP)</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (7-11 Yrs)</title>
          <description>Safety population (SP)</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (12-17 Yrs)</title>
          <description>Safety population (SP)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to insect sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Inappetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Incoordination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Psychomotor agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Equilibrium trouble</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Intention tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggressive behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aggression aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>BIAL - Portela &amp; Cª, SA</organization>
      <phone>+351-22 9866100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

